BiotechTV - News

Connor Landgraf shows us the product and describes recent data the company compiled in the UK showing the benefits of using this digital and AI enhanced device over a traditional stethoscope.

He describes the raise and the trial, which is an umbrella study that will test products against three different mutations. Plus, work on vaccines and a non-oncology cell therapy program, and partnership opportunities.

CEO Per Andersson walks us through the benefits of designing kinase inhibitors this way, which should not be affected by the pH of the stomach. He shows us the unique manufacturing equipment, and walks us through a pipeline that includes dasatinib, nilotinib, axitinib, and cabozantinib.

CEO Nicklas Westerholm walks us through the condition, which is an X-chromosome linked rare disease that affects men, and he describes how the launch is going in Europe, and plans for an FDA meeting.

CEO Christer Ahlberg describes the shortcomings of today's medicines, and why he believes a P-CAB is the answer. This therapy originated at AstraZeneca, though Cinclus owns it outright today, and is in a phase 3 that just started.

He sees an optimistic turn after a challenging couple of years. Plus, highlighting Vicor, Camurus, Oculis, and BioArctic.

CEO Thomas Feldthus describes the challenge of making ion channel medicines selective enough to avoid unwanted side effects. He walks us through the Jazz and Acadia partnership, and highlights three other internally developed programs.

She describes the transferrin receptor based brain transporter technology, which the company recently signed another new partner (Novartis) on for $30M up front. Plus, the European approval of Leqembi, and how the Parkinson's program is progressing.

He describes the science behind the A1M protein that this is based on, and how Guard has chosen kidney protection for patients who are undergoing heart surgery as the lead indication. We walk through various scenarios ahead of the upcoming readout.

CEO Martin Welschof walks us through these two programs, which both target liquid and solid tumors. BI-1808 recently had data at EHA and will have solid tumor data later this year, while 2026 will be data rich for BI-1206.

CEO David Veitch walks us through the U.S. launch of Zevtera, and discusses where Cresemba is in its global commercial lifecycle. Plus, pipeline progress, and how Basilea's experience with BARDA funding has been a good sign of consistency for the field.

Christophe Weber discusses the 25 year journey from the discovery that orexin deficiency is the cause of narcolepsy to announcing two positive phase three studies with an agonist. He shares highlights of the World Sleep Congress data, and how he views emerging competitors in the class.

Founding Partner Stephen Thompson and Partner Jonathan Tobin list some of their recent investments, highlight the advantage of running speedy clinical trials in Australia, and comment on what the benefits to life sciences would be if the UK would allow pensions to invest in private venture funds.

Dr. Berger, whose experience in biotech goes back decades, including founding and running ARIAD for 25 years, is taking over this company that was publicly launched at the beginning of 2024 and came with it a funding commitment of up to $500 million from large investors.

CEO Neil Miller walks us through the hypothesis of how toxic proteins created by neurodegenerative diseases enter and damage the mitochondria, and how the company's small molecule inhibitors are meant to block this. With these funds, the company can enter the clinic in Parkinson's in early 2026.

Co-Founder and CEO Eran Eshed describes the unmet need and how CHLOE Blast analyzes images from a time-laps incubator.

He describes how the idea is to cut down on control arm overlap used in numerous trials. If successful, it might free up space and resources to run faster and more efficient trials, and offer more participants a chance to be in experimental arms.

He shares what he believes the takeaways are from MAPLE-HCM, which studied aficamten vs a beta blocker in symptomatic obstructive hypertrophic cardiomyopathy patients. Plus, learnings from a competitor's data in non-obstructive HCM, and the status of the company's regulatory review.

Launched publicly today, and funded with $50M at this point, Corsera Health hopes to target those who are most at risk for atherosclerotic cardiovascular disease from an early age. The goal is to extend lives with an annual medicine by lowering LDL and blood pressure.

Trey Holterman describes how Tennr is trying to fix this process which relies on significant unstructured data and has traditional leads to onerous delays and unnecessary rejections.

Dr. Zou describes this work, which was published recently in Nature, and how the the AI scientists were able to do everything from debate internally to narrow down candidates from numerous possibilities.

He shares his take on today's data, which saw Viking's stock decline by over 40%, and Lilly's earlier data which also sparked a Wall Street disappointment. He describes whether he agrees with the reactions or not, and how the totality of the obesity market is shaping up.

Nucleate leaders describe what Nucleate has done for their education and career, and what they are looking forward to at this year's global summit in Boston.

Founder & CEO Ashoka Rejendra describes what the company offers, which is a not only a software package, but guidance on how to build and plan for the future. New entrepreneurs like those attending the Nucleate Summit are a natural prospect.

In this inaugural episode of Biotech Direct, BiotechTV's new show that will share the biotech industry's perspective on policy and regulatory news, Kendalle Burlin O'Connell and Daphne Zohar discuss the strategic importance of biotech to the United States, share their thoughts on new FDA initiatives, and brainstorm ways to raise public awareness of the importance of science.